[{"address1": "3 Temasek Avenue", "address2": "Level 18 Centennial Tower", "city": "Singapore", "zip": "039190", "country": "Singapore", "phone": "65 6817 9598", "website": "https://aslanpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.", "age": 50, "title": "Founder, CEO & Executive Director", "yearBorn": 1973, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kiran Kumar  Asarpota", "age": 44, "title": "COO & Head of Finance", "yearBorn": 1979, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ben  Goodger", "age": 60, "title": "General Counsel", "yearBorn": 1963, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen  Doyle", "age": 50, "title": "Chief Business Officer", "yearBorn": 1973, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alexandre  Kaoukhov M.D.", "age": 49, "title": "Chief Medical Officer", "yearBorn": 1974, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Charlie  Hsu", "title": "Investor Relations Director", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Chi-Chin  Wang", "title": "IR & Corporate Development Director", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 0.6999, "open": 0.63, "dayLow": 0.6, "dayHigh": 0.6999, "regularMarketPreviousClose": 0.6999, "regularMarketOpen": 0.63, "regularMarketDayLow": 0.6, "regularMarketDayHigh": 0.6999, "beta": 1.399, "forwardPE": -0.031914897, "volume": 769822, "regularMarketVolume": 769822, "averageVolume": 102101, "marketCap": 1697010, "fiftyTwoWeekLow": 0.475, "fiftyTwoWeekHigh": 17.52, "priceToSalesTrailing12Months": 0.1414175, "fiftyDayAverage": 1.731334, "twoHundredDayAverage": 3.9664054, "currency": "USD", "enterpriseValue": 288325824, "profitMargins": -2.9189003, "floatShares": 410329771, "sharesOutstanding": 2828350, "sharesShort": 38320, "sharesShortPriorMonth": 37172, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.0135, "heldPercentInsiders": 0.0013799999, "heldPercentInstitutions": 0.13207, "shortRatio": 1.85, "shortPercentOfFloat": 0.0146, "impliedSharesOutstanding": 24382000, "bookValue": -7.698, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -35026764, "trailingEps": -16.0, "forwardEps": -18.8, "lastSplitFactor": "1:8", "lastSplitDate": 1719964800, "enterpriseToRevenue": 24.027, "enterpriseToEbitda": -8.263, "52WeekChange": -0.96511626, "SandP52WeekChange": 0.24822903, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ASLN", "underlyingSymbol": "ASLN", "shortName": "ASLAN Pharmaceuticals Limited", "longName": "ASLAN Pharmaceuticals Limited", "firstTradeDateEpochUtc": 1525440600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "64d5d950-3f7f-30f1-9c3d-4a28bad97a03", "messageBoardId": "finmb_419159771", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.6, "targetHighPrice": 72.0, "targetLowPrice": 72.0, "targetMeanPrice": 72.0, "targetMedianPrice": 72.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 18396364, "totalCashPerShare": 0.039, "ebitda": -34893432, "totalDebt": 26665472, "quickRatio": 0.938, "currentRatio": 1.05, "totalRevenue": 12000000, "revenuePerShare": 5.514, "returnOnAssets": -0.53692, "grossMargins": 1.0, "ebitdaMargins": -2.90779, "operatingMargins": -2.9103, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-15"}]